SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2702twitter.com!/search?q=%23ASH11 Twit Central.scaram(o)uche-12/9/2011
2701Chuckle. Thanks! Happy Thanksgiving!scaram(o)uche-11/23/2011
2700By puzzlement was that it shows JAK2 as having a lower IC50 than JAK1 - usually Biomaven-11/23/2011
2699>> Sloppy << And one more comment.... looks like there might be soscaram(o)uche-11/23/2011
2698While we're on this subject, what tools do folks use to routinely/accuratelyscaram(o)uche-11/23/2011
2697Anyone who followed Crucell probably has respect for these guys. Innovative. Butscaram(o)uche-11/23/2011
2696Yes, the slide is designed to show (and shows) selective JAK1 activity. But it scaram(o)uche-11/23/2011
2695<i>Galapagos molecule has JAK2 activity (slide 9)</i> I think the sBiomaven-11/23/2011
2694As you noted, the Galapagos molecule has JAK2 activity (slide 9). Here's thescaram(o)uche-11/23/2011
2693Et tu, Amgen?? ncbi.nlm.nih.gov ncbi.nlm.nih.gov (The discussion sections mascaram(o)uche-11/23/2011
2692Since mcbio , Dew and pgs were discussing jak1 vs jak2 on ihub, here is the mostsoftware salesperson-11/23/2011
2691Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients A.J. Mullen-11/20/2011
2690Agreed with everything you said, Biomaven. BTW, I did too just like you.quantman-11/17/2011
2689<i>Name kind of sucks, though</i> Agreed. But it's really toughBiomaven-11/17/2011
2688>> Name kind of sucks << Yup, but if you're trying to carry aroscaram(o)uche-11/16/2011
2687Great news, even if expected. Name kind of sucks, though.tommysdad-11/16/2011
2686<i>trading resumes, 11:45</i>..... FDA NEWS RELEASE For Immediate scaram(o)uche-11/16/2011
2685halted, notice of approval just coming thru.....scaram(o)uche-11/16/2011
2684Mayo Clin Proc. 2011 Oct 27. [Epub ahead of print] Serious Adverse Events Duriscaram(o)uche-10/30/2011
2683Like many of you, I too was taken aback from the 'Tefferi et al' Letter quantman-10/14/2011
2682I've now seen some analyst reports defending INCY, and they make some reasonBiomaven-10/14/2011
2681<<Someone on Drew's board pointed out that the author of that letter tnsaf-10/13/2011
2680Well steroids get tapered and I believe methotrexate does too. So it's not jBiomaven-10/13/2011
2679I am aware of tapering drugs in the treatment of anxiety and sleep disorders to Biotech Jim-10/13/2011
2678>> rebound effect I guess I'm not as concerned about this - first thiBiomaven-10/13/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News